Market Overview

U.S. Approval Of PTC Therapeutics' Translarna 'Remains Unlikely'

U.S. Approval Of PTC Therapeutics' Translarna 'Remains Unlikely'
Related PTCT
The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering
The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs
ProShares Nasdaq Biotech ETF And Holdings Review For Buys (Seeking Alpha)

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) gained more than 13 percent Friday after the FDA found that the company's experimental drug to treat Duchenne muscular dystrophy may work.

The FDA's Advisory Committee meeting ruled that the body of evidence for the company's ataluren therapy was inconclusive by a 10 to 1 vote, Credit Suisse's Alethia Young said in a Friday note. This result was in-line with what the analyst was expecting, as it showed a positive benefit trend but wasn't sufficient enough to show any statistical significance.

"Based on the stock move with the briefing documents, we think that ataluren not getting approved in the U.S. is baked in," Young said. (See Young's track record here.) 

It's important to note that PTC's stock initially traded lower by more than 10 percent after the announcement on Thursday, but quickly recovered to erase the losses and then move higher Friday.

PTC will likely provide an update on protein level data at the World Muscle Society medical meeting on Oct. 5, according to Credit Suisse. Roche will likely begin pivotal studies on a therapy of its own later in 2017, according to the research firm. 

PTC's developments should have no read through to Sarepta Therapeutics Inc (NASDAQ: SRPT)'s Exondys 51's ongoing launch or potential development plans, Young said. Exondys 51 was "approved on the surrogate dystrophin endpoint that the FDA reiterated as valid."

Related Links:

Sarepta Marks A 'Very Important Day' For The DMD Community

Exclusive: Capricor CEO Talks Exondys Competition

Latest Ratings for PTCT

Nov 2018Cantor FitzgeraldMaintainsOverweightOverweight
Nov 2018RBC CapitalMaintainsOutperformOutperform
Nov 2018BarclaysMaintainsEqual-WeightEqual-Weight

View More Analyst Ratings for PTCT
View the Latest Analyst Ratings

Posted-In: Alethia Young atalurenAnalyst Color News Health Care FDA Analyst Ratings General Best of Benzinga


Related Articles (SRPT + PTCT)

View Comments and Join the Discussion!

Latest Ratings

CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Mid-Afternoon Market Update: Envirostar Drops After Fiscal 2017 Results; Zogenix Shares Spike Higher

What The T12 Halt Means For root9B Shareholders